Canagliflozin versus placebo for post-bariatric surgery patients with persistent type II diabetes: A randomized controlled trial (CARAT)

Diabetes Obes Metab. 2017 Apr;19(4):609-610. doi: 10.1111/dom.12860. Epub 2017 Feb 9.

Authors

Karim Kheniser¹, Sangeeta R Kashyap¹

Affiliation

¹ Department of Endocrinology and Metabolism, Cleveland Clinic, Cleveland, Ohio.

PMID: 27995724
DOI: 10.1111/dom.12860

No abstract available

Publication types

Letter
Randomized Controlled Trial

MeSH terms

Adult
Aged
Bariatric Surgery*
Blood Glucose / drug effects
Blood Glucose / metabolism
Canagliflozin / therapeutic use*
Combined Modality Therapy
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / surgery*
Female
Glycated Hemoglobin / drug effects
Glycated Hemoglobin / metabolism
Humans
Male
Middle Aged
Placebos
Postoperative Period
Treatment Failure
Young Adult

Substances

Blood Glucose
Glycated Hemoglobin A
Placebos
hemoglobin A1c protein, human
Canagliflozin